Cost-effectiveness analysis of selective first-line use of biologics for unresectable RAS wild-type left-sided metastatic colorectal cancer.
| Autor: | Wong, W. W. L.1 wwlwong@uwaterloo.ca, Zargar, M.1, Berry, S. R.2, Ko, Y. J.3, Riesco-Martínez, M.4, Chan, K. K. W.3,5 |
|---|---|
| Zdroj: | Current Oncology. Oct2019, Vol. 26 Issue 5, pe597-e609. 13p. 1 Diagram, 6 Charts, 2 Graphs. |
| Databáze: | Academic Search Ultimate |
| Externí odkaz: |
|